Combinational drug-loaded lipid nanocapsules for the treatment of cancer

Int J Pharm. 2019 Oct 5:569:118588. doi: 10.1016/j.ijpharm.2019.118588. Epub 2019 Aug 1.

Abstract

The purpose of this study was to investigate the feasibility of an intravenously administered combinational therapy using lipid nanocapsules (LNCs) as a drug delivery carrier for the treatment of different cancers. Therefore, we encapsulated 6 anticancer drugs within LNCs. Their size was approximately 50 nm. Except for oxaliplatin, their encapsulation efficiency, which was measured by different analytical methods, varied between 75% for SN38 to 100% for regorafenib. The in vitro studies showed a nonsignificant difference between the cytotoxicity of free and encapsulated drugs and a significant decrease in haemolysis by encapsulation in LNCs. Finally, the in vivo experiment showed that a combinational regimen of SN38-LNCs and regorafenib-LNCs abates CT26 murine colorectal cancer growth and increases median survival time.

Keywords: Colorectal cancer; Lipid nanocapsules; Regorafenib; SN38.

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Cell Line, Tumor
  • Drug Combinations
  • Erythrocytes / drug effects
  • Female
  • Hemolysis / drug effects
  • Humans
  • Irinotecan / administration & dosage*
  • Lipids / administration & dosage
  • Mice, Inbred BALB C
  • Nanocapsules / administration & dosage*
  • Neoplasms / drug therapy*
  • Phenylurea Compounds / administration & dosage*
  • Pyridines / administration & dosage*

Substances

  • Antineoplastic Agents
  • Drug Combinations
  • Lipids
  • Nanocapsules
  • Phenylurea Compounds
  • Pyridines
  • regorafenib
  • Irinotecan